Cholangiocarcinoma

Gunagratinib is being investigated in an ongoing phase 2a dose-expansion study in patients with cholangiocarcinoma.

Results of the SWOG 1815 study failed to demonstrate a benefit with the addition of nab-paclitaxel to gemcitabine/cisplatin (GemCis) versus GemCis alone.

In the JCOG1202 subgroup analysis, researchers analyzed risk factors for early relapse in patients with biliary tract cancer undergoing surgical resection.

Researchers aimed to assess characteristics, outcomes, and genomic profiles of long-term survivors treated with durvalumab plus gemcitabine/cisplatin (GemCis) or placebo plus GemCis in the TOPAZ-1 trial.

IMbrave 151 examined the efficacy of the PD-L1 inhibitor atezolizumab with or without the VEGF inhibitor bevacizumab, and gemcitabine/cisplatin as first-line treatments in patients with advanced biliary tract cancer.

A single-arm, phase 2 study investigated the safety and efficacy of second-line nab-paclitaxel combined with the anti–PD-1 antibody sintilimab in patients with advanced biliary tract cancer.

This phase 2 randomized trial assessed stereotactic body radiation and the anti–PD-1 drug nivolumab with or without the anti-CTLA4 drug ipilimumab in patients with metastatic biliary tract cancer.

This study examined the costs of treatment with gemcitabine/cisplatin with or without durvalumab in patients with advanced cholangiocarcinoma.

In the phase 3 Nutide:121 study, NUC-1031 plus cisplatin was compared with gemcitabine/cisplatin for first-line treatment of patients with advanced biliary tract cancer.

A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.